Search
START Phage WA was formed to pave the way towards treating AMR infections with phage therapy in Western Australia.
Community involvement plays an integral role in guiding our research - find out how.
The Western Australian Epithelial Research Program (WAERP) is a community cohort biobank that collects and stores airway cells from the upper (nose) and lower (trachea) airways of Western Australian children and adults (1-50 years of age) undergoing non respiratory elective surgery.
The Western Australian Epithelial Research Program (WAERP) biobank is undertaking a number of research projects intended to improve the understanding and preclinical assessment of therapeutics for respiratory conditions.
News & Events
Pre-term kids get green light to exerciseParents of children born prematurely have expressed concerns about their child’s lung health when they exercise, with symptoms such as breathlessness.
News & Events
Bushfires: Tips to protect family from smoke exposurePerth’s north-east is under threat from an out-of-control bushfire.
News & Events
Enhancing the lung health for preterm birth survivors by uncovering treatable traitsA project to uncover treatable traits to improve the lung health of people born preterm has been made possible thanks to a $1.99 million Medical Research Future Fund (MRFF) grant.
News & Events
Community partnership sets priorities for preterm lung health researchRespiratory disease remains one of the most significant complications of preterm birth, with lasting consequences.
News & Events
New funding to accelerate AI personalised phage therapiesWal-yan researchers have been awarded $500,000 for their innovative research, supported by the Western Australian Government’s Future Health Medical Research and Innovation (FHRI) Fund.
Research
BEAT-CF (Bayesian Evidence Adaptive Treatment for people with Cystic Fibrosis): description of a prospective cohort for nested studies in cystic fibrosisDespite recent improvements in treatment modalities for cystic fibrosis (CF), there is currently limited evidence and a lack of consensus regarding optimal treatment strategies for the different aspects of CF, including pulmonary exacerbations (PEx). We aimed to establish a prospective cohort of people with CF (pwCF) to evaluate alternative approaches to managing CF in the era of modulator therapies.